Upstate Clinical Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$13,341	23
2024	Research	$677,353	20
2023	Research	$4,704	13
2021	Research	$5,116	3
2019	Research	$192	4

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $694,558 44 payments
Myovant Sciences Inc. $5,116 3 payments
GRT US Holding, Inc. $840 12 payments
Pfizer Inc. $192 4 payments

Studies the money was for Research payments · program years 2019–2025

A Multicentre Randomized, Double-Blind, Placebo-Controlled, Dose-Findi $657,413 38 payments
A Multicenter Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu $37,145 6 payments
An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids $5,116 3 payments
A Randomized Doubleblind Placebocontrolled Phase III Trial to Evaluate the Efficacy and Safety of A Single Intraarticular Injection of Rtxgrt7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee $840 12 payments
A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $192 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.